Paper Details

  1. Home
  2. Paper Details

The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.

Author: DengShin-Tarng, HsuChao-Wei, TsaiTzu-Cheng

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Elbasvir/grazoprevir (EBR/GZR) is safe and effective for treating patients with chronic hepatitis C virus (HCV) genotype (GT) 1, exhibiting excellent overall clinical efficacy in Taiwan. The therapeutic effects were unrelated to factors such as sex, HCV RNA level before treatment, and history of liver cirrhosis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Elbasvir/grazoprevir (EBR/GZR) is a new generation, fixed-dose, combination antiviral drug used in chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 infection. Our study evaluates the clinical efficacy and safety of EBR/GZR after its launch in Taiwan. METHODS: This is a retrospective...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916308/

データ提供：米国国立医学図書館（NLM）

Elbasvir/Grazoprevir: A New Era in HCV Treatment

Hepatitis C virus (HCV) infection can have serious consequences for liver health. This research, like a camel caravan seeking a safe passage through a challenging desert environment, evaluates the efficacy and safety of elbasvir/grazoprevir (EBR/GZR), a new generation antiviral drug for treating HCV genotype 1 infections.

A Promising New Treatment for HCV

The study found that EBR/GZR is safe and effective for treating HCV genotype 1 infections, with a high rate of sustained virologic response (SVR12). This promising new treatment offers hope for individuals with HCV infection, like a camel caravan finding a refreshing oasis in a desolate desert. It provides a potential path towards recovery and a healthier future.

A Step Towards a Cure for HCV

This research underscores the ongoing advancements in HCV treatment and the quest for a cure. It highlights the importance of continued research and development of new and effective antiviral therapies to combat this challenging infection. It's like a camel caravan, adapting to changing conditions and seeking the most effective way to navigate the challenges of a harsh desert environment.

Dr.Camel's Conclusion

Elbasvir/grazoprevir offers a promising new treatment option for HCV genotype 1 infections, providing a high rate of sustained virologic response. This research represents a significant step forward in the fight against HCV and encourages continued research and development of new and effective therapies.

Date :
  1. Date Completed 2020-12-07
  2. Date Revised 2021-01-10
Further Info :

Pubmed ID

31599455

DOI: Digital Object Identifier

PMC6916308

Related Literature

Article Analysis
・Side Effects of elbasvir and grazoprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.